XERS News and Press, Xeris Pharmaceuticals Inc. From 03/16/21

Penny Stock News Triggers Momentum In These Cheap Stocks When it comes to penny stocks, there are plenty of different catalysts to consider. You could look for general market trends or sector/industry-based themes. However, these are more along the line of technical catalysts. On the ot...

Xeris Pharmaceuticals (XERS) priced its registered direct offering of 6.55M shares, par value $0.0001/share to funds managed by existing investors Deerfield Management, at $4.12/share for gross proceeds of $27M.Net proceeds to be used for general corporate purposes.Offer expected to close on ...

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced the pricing of a registered direct offering of 6,553...

Xeris Pharmaceuticals, Inc. (XERS) Q4 2020 Earnings Conference Call March 09, 2021 08:30 AM ET Company Participants Allison Wey - Senior Vice President of Investor Relations Paul Edick - Chairman & Chief Executive Officer Barry Deutsch - Chief Financial Officer Conference Call Participant...

Xeris Pharmaceuticals (XERS): Q4 GAAP EPS of -$0.41 misses by $0.01.Revenue of $7.09M (+335.0% Y/Y) misses by $1.82M.Press Release For further details see: Xeris Pharmaceuticals EPS misses by $0.01, misses on revenue

Gvoke® net sales of $20.2 million for full-year 2020 Continued Gvoke prescription growth – over 350% in 2020 Strong cash position of $133.8 million Conference call and webcast today at 8:30 a.m. ET Xeris Pharmaceuticals, Inc. (Nasdaq: XERS...

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that the Company will release its fourth quarter and...

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that Paul R. Edick, Chairman and Chief Executive Officer of Xe...

Xeris Pharmaceuticals continues to pop up on my newsfeed and momentum scanners. Unfortunately, I threw XERS in my speculative portfolio's closet and haven't paid attention despite it hitting new 52-week highs. The company recently received European approval for their premixed RTU liqu...

Today, we take an in-depth look at specialty pharmaceutical concern Xeris Pharmaceuticals. The company has two approved products developed using their proprietary technology platform. A full investment analysis is as follows. For further details see: The Latest On Xeris ...